Description
Key facts
Cell type:A549,
Species or organism:Human,
Tissue:Lung,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, Homozygous: 11 bp deletion in exon3.,
Disease:Carcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-IRF7, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Zygosity-Homozygous, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The transcription factor IRF7 also known as Interferon Regulatory Factor 7 plays a significant role in the regulation of type I interferon genes. This protein acts as an important modulator of the immune response specifically during viral infections. The molecular weight of IRF7 is approximately 54 kDa. It is predominantly expressed in lymphoid tissues such as the spleen and thymus and is also found in other immune cells like B cells and dendritic cells. The expression of IRF7 is induced by pathogen-associated molecular patterns which stimulate the activation of immune signaling pathways.
Biological function summary
IRF7 activates and modulates the expression of type I interferons and other cytokines important for antiviral defense. This protein can form part of a larger complex with other IRF family members to enhance its effect on gene transcription. IRF7 operates through its interaction with transcriptional coactivators allowing it to execute its function as a transcriptional activator reinforcing the immune system's response to infectious agents.
Pathways
IRF7 plays a critical role in the Toll-like receptor (TLR) signaling pathway and retinoic acid-inducible gene I (RIG-I) pathway. It directly interacts with MyD88 and IRAK1 proteins linking it to signal transduction pathways that lead to interferon-beta production. The activation of IRF7 in these pathways also strengthens the body's defense mechanism by enhancing the transcription of antiviral genes forming a robust antibacterial and antiviral environment within the host.
IRF7's function is implicated in autoimmune diseases and specific cancers. For autoimmune conditions like systemic lupus erythematosus (SLE) dysregulated IRF7 activity is observed leading to an aberrant interferon response. It connects with proteins such as IRF5 which has its expressions elevated in affected patients. In relation to cancer IRF7 can impact tumor progression particularly in breast cancer through modulation of immune surveillance functions. Its interaction with interferon pathways becomes a double-edged sword affecting tumor immunity and progression.
